COPD is characterised by airflow obstruction and episodes of acute deterioration in respiratory health, termed ‘exacerbations’, which account for much of the morbidity, mortality, hospitalisations, and worsening of quality of life. The majority of costs in patients with COPD are related to treatment of exacerbations, with hospitalisation costs as a major component. Hospitalised patients with COPD often have
comorbidities that increase the length of hospital stay and lead to higher cost and mortality rates.